Brussels, 22/07/2014 (Agence Europe) - On Tuesday 22 July, the European Commission gave the go-ahead to the creation of a joint venture by Allergopharma GmbH & Co. KG of Germany, Stallergenes S.A. of France and Laboratorios LETI, S.L. Unipersonal of Spain. Allergopharma is active in the fields of allergen immunotherapy, allergy diagnostics and allergy prevention in 25 countries, but mostly in Germany; Stallergenes is a global healthcare company specialised in the diagnosis and treatment of allergies in 20 countries and in the sale of solutions in 75 countries; and LETI is a biopharmaceutical company active in the fields of treatment and diagnosis of allergies and pharmaceutical skincare, in-vitro diagnostics and vaccines with manufacturing sites in Madrid and subsidiaries in Spain and Portugal. The joint venture will develop mobile environmental exposure chambers for carrying out studies on new preparations for the treatment of allergies. It will obtain all validations and permits that are necessary for its operation and will then market the mobile chambers. The Commission concluded that the proposed acquisition would not raise competition concerns, because the joint venture is expected to generate low turnover in the European Economic Area (EEA) and the total value of the assets transferred to the joint venture in the EEA is limited. (EL)